Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant trial of anastrozole versus fulvestrant in operable hormone receptor-positive breast cancer
2006-006409-10Phase 2Active
- Sponsor
- Unicancer
- Start
- Feb 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Anastrozole arm with Fulvestrant arm (2 arms). Primary endpoints: Clinical tumor response rate at 6 months, Complete response rate at 6 months and 1 more. Started Feb 2007; status: active.
02
Drugs
anastrozolefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-006409-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006409-10.